112 related articles for article (PubMed ID: 23379820)
1. Promoter hypermethylation contributes to TIMP3 down-regulation in high stage endometrioid endometrial carcinomas.
Catasus L; Pons C; Muñoz J; Espinosa I; Prat J
Histopathology; 2013 Mar; 62(4):632-41. PubMed ID: 23379820
[TBL] [Abstract][Full Text] [Related]
2. Hypermethylation in the p16 promoter region in the carcinogenesis of endometrial cancer in Japanese patients.
Yanokura M; Banno K; Susumu N; Kawaguchi M; Kuwabara Y; Tsukazaki K; Aoki D
Anticancer Res; 2006; 26(2A):851-6. PubMed ID: 16619479
[TBL] [Abstract][Full Text] [Related]
3. Hypermethylation of RAS effector related genes and DNA methyltransferase 1 expression in endometrial carcinogenesis.
Liao X; Siu MK; Chan KY; Wong ES; Ngan HY; Chan QK; Li AS; Khoo US; Cheung AN
Int J Cancer; 2008 Jul; 123(2):296-302. PubMed ID: 18404674
[TBL] [Abstract][Full Text] [Related]
4. Methylation profiles of endometrioid and serous endometrial cancers.
Seeber LM; Zweemer RP; Marchionni L; Massuger LF; Smit VT; van Baal WM; Verheijen RH; van Diest PJ
Endocr Relat Cancer; 2010 Sep; 17(3):663-73. PubMed ID: 20488783
[TBL] [Abstract][Full Text] [Related]
5. Microsatellite instability in endometrioid type endometrial adenocarcinoma is associated with poor prognostic indicators.
An HJ; Kim KI; Kim JY; Shim JY; Kang H; Kim TH; Kim JK; Jeong JK; Lee SY; Kim SJ
Am J Surg Pathol; 2007 Jun; 31(6):846-53. PubMed ID: 17527071
[TBL] [Abstract][Full Text] [Related]
6. Loss of expression of TIMP3 in clear cell renal cell carcinoma.
Masson D; Rioux-Leclercq N; Fergelot P; Jouan F; Mottier S; Théoleyre S; Bach-Ngohou K; Patard JJ; Denis MG
Eur J Cancer; 2010 May; 46(8):1430-7. PubMed ID: 20194016
[TBL] [Abstract][Full Text] [Related]
7. Frequent hypermethylation of MLH1 promoter in normal endometrium of patients with endometrial cancers.
Kanaya T; Kyo S; Maida Y; Yatabe N; Tanaka M; Nakamura M; Inoue M
Oncogene; 2003 Apr; 22(15):2352-60. PubMed ID: 12700670
[TBL] [Abstract][Full Text] [Related]
8. High frequency of RASSF1A and RARb2 gene promoter methylation in morphologically normal endometrium adjacent to endometrioid adenocarcinoma.
Arafa M; Kridelka F; Mathias V; Vanbellinghen JF; Renard I; Foidart JM; Boniver J; Delvenne P
Histopathology; 2008 Nov; 53(5):525-32. PubMed ID: 18783461
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling of microsatellite unstable and microsatellite stable endometrial cancers indicates distinct pathways of aberrant signaling.
Risinger JI; Maxwell GL; Chandramouli GV; Aprelikova O; Litzi T; Umar A; Berchuck A; Barrett JC
Cancer Res; 2005 Jun; 65(12):5031-7. PubMed ID: 15958545
[TBL] [Abstract][Full Text] [Related]
10. Abnormalities of the APC/beta-catenin pathway in endometrial cancer.
Moreno-Bueno G; Hardisson D; Sánchez C; Sarrió D; Cassia R; García-Rostán G; Prat J; Guo M; Herman JG; Matías-Guiu X; Esteller M; Palacios J
Oncogene; 2002 Nov; 21(52):7981-90. PubMed ID: 12439748
[TBL] [Abstract][Full Text] [Related]
11. Promoter hypermethylation and expression of sprouty 2 in endometrial carcinoma.
Velasco A; Pallares J; Santacana M; Gatius S; Fernandez M; Domingo M; Valls J; Yeramian A; Encinas M; Dolcet X; Matias-Guiu X
Hum Pathol; 2011 Feb; 42(2):185-93. PubMed ID: 21111454
[TBL] [Abstract][Full Text] [Related]
12. Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only.
De Schutter H; Geeraerts H; Verbeken E; Nuyts S
Oncol Rep; 2009 Feb; 21(2):507-13. PubMed ID: 19148529
[TBL] [Abstract][Full Text] [Related]
13. Hypermethylation of miR-203 in endometrial carcinomas.
Huang YW; Kuo CT; Chen JH; Goodfellow PJ; Huang TH; Rader JS; Uyar DS
Gynecol Oncol; 2014 May; 133(2):340-5. PubMed ID: 24530564
[TBL] [Abstract][Full Text] [Related]
14. Positive correlation of tissue inhibitor of metalloproteinase-3 and death-associated protein kinase hypermethylation in head and neck squamous cell carcinoma.
Nayak CS; Carvalho AL; Jeronimo C; Henrique R; Kim MM; Hoque MO; Chang S; Jiang WW; Koch W; Westra W; Sidransky D; Califano J
Laryngoscope; 2007 Aug; 117(8):1376-80. PubMed ID: 17592394
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of the candidate tumor suppressor par-4 in endometrial cancer.
Moreno-Bueno G; Fernandez-Marcos PJ; Collado M; Tendero MJ; Rodriguez-Pinilla SM; Garcia-Cao I; Hardisson D; Diaz-Meco MT; Moscat J; Serrano M; Palacios J
Cancer Res; 2007 Mar; 67(5):1927-34. PubMed ID: 17332319
[TBL] [Abstract][Full Text] [Related]
16. Assessment of hypermethylated DNA in two promoter regions of the estrogen receptor alpha gene in human endometrial diseases.
Hori M; Iwasaki M; Shimazaki J; Inagawa S; Itabashi M
Gynecol Oncol; 2000 Jan; 76(1):89-96. PubMed ID: 10620447
[TBL] [Abstract][Full Text] [Related]
17. Epithelial to mesenchymal transition in early stage endometrioid endometrial carcinoma.
Montserrat N; Mozos A; Llobet D; Dolcet X; Pons C; de Herreros AG; Matias-Guiu X; Prat J
Hum Pathol; 2012 May; 43(5):632-43. PubMed ID: 21940036
[TBL] [Abstract][Full Text] [Related]
18. Alterations in the tissue inhibitor of metalloproteinase-3 (TIMP-3) are found frequently in human colorectal tumours displaying either microsatellite stability (MSS) or instability (MSI).
Brueckl WM; Grombach J; Wein A; Ruckert S; Porzner M; Dietmaier W; Rümmele P; Croner RS; Boxberger F; Kirchner T; Hohenberger W; Hahn EG; Jung A
Cancer Lett; 2005 Jun; 223(1):137-42. PubMed ID: 15890246
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation and promoter methylation of tissue inhibitor of metalloproteinase 3 in choriocarcinoma.
Feng H; Cheung AN; Xue WC; Wang Y; Wang X; Fu S; Wang Q; Ngan HY; Tsao SW
Gynecol Oncol; 2004 Aug; 94(2):375-82. PubMed ID: 15297175
[TBL] [Abstract][Full Text] [Related]
20. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
Alvarez T; Miller E; Duska L; Oliva E
Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
